Hospital
University of California San Francisco Medical Center
University of California San Francisco Medical Center was paid $54.08M by Medicaid between Jan 2018 and Dec 2024, across 453 billing codes. Its largest line is 99202, Office or other outpatient visit for the evaluation and management of a new patient, straightforward — 15% of everything it billed.
33Billing provider infoUNIVERSITY OF CALIFORNIA SAN FRANCISCO MEDICAL CENTER
SAN FRANCISCO, CA 94143
SAN FRANCISCO, CA 94143
33aNPI1639278369assigned 09/21/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$54.08M
24GClaims785,290
24DCodes billed453
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#55 of 410
Median peer was paid$6.90M
This provider vs. median7.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 108,223 | $5.15M | |
| 2019 | 116,736 | $6.87M | |
| 2020 | 86,271 | $6.75M | |
| 2021 | 120,061 | $8.48M | |
| 2022 | 128,852 | $8.60M | |
| 2023 | 120,327 | $8.23M | |
| 2024incomplete | 104,820 | $10.00M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 15% | 73,238 | 56,280 | $7.94M |
| 99201 | 8.0% | 54,132 | 43,571 | $4.31M | |
| Q3014 | Telehealth originating site facility fee | 6.9% | 75,679 | 68,561 | $3.72M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 4.7% | 3,023 | 2,969 | $2.53M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.5% | 17,932 | 16,649 | $2.45M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 3.5% | 11,518 | 7,870 | $1.88M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.2% | 46,738 | 44,670 | $1.73M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.0% | 22,986 | 22,521 | $1.64M |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 2.5% | 1,889 | 1,869 | $1.35M |
| 0760 | 2.2% | 20,989 | 19,856 | $1.17M | |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 2.1% | 995 | 464 | $1.15M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 2,198 | 2,142 | $1.08M |
441 more codes
| 99283 | Emergency room visit (moderate) | 2.0% | 15,895 | $1.07M |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.8% | 2,039 | $954K |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.6% | 209 | $842K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.5% | 7,299 | $830K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 3,748 | $801K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.4% | 9,780 | $760K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 1.3% | 5,115 | $726K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 2,046 | $717K |
| 80053 | Comprehensive metabolic panel | 1.2% | 16,693 | $643K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 1.0% | 1,139 | $561K |
| 0450 | Emergency room services | <1% | 3,650 | $497K |
| 93325 | <1% | 2,326 | $485K | |
| 72197 | <1% | 834 | $481K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 27,217 | $409K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,322 | $405K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 6,212 | $400K |
| 88341 | <1% | 1,246 | $375K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 82 | $315K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 389 | $305K |
| 87799 | <1% | 2,167 | $303K | |
| 74183 | <1% | 493 | $296K | |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 27 | $289K |
| 92557 | <1% | 1,816 | $280K | |
| J3490 | Unclassified drugs | <1% | 5,956 | $266K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,144 | $264K |
| 71250 | <1% | 742 | $251K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,070 | $205K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,141 | $195K |
| 92567 | <1% | 3,360 | $189K | |
| 59426 | <1% | 1,190 | $165K | |
| J2704 | Injection, propofol, 10 mg | <1% | 10,785 | $165K |
| G9002 | Coordinated care fee, maintenance rate | <1% | 1,227 | $160K |
| 83735 | <1% | 7,472 | $156K | |
| 88342 | <1% | 2,200 | $150K | |
| 99070 | <1% | 4,527 | $147K | |
| T1024 | Evaluation and treatment by an integrated, specialty team contracted to provide coordinated care to multiple or severely handicapped children, per encounter | <1% | 2,222 | $143K |
| 0510 | <1% | 2,270 | $142K | |
| 76770 | <1% | 1,049 | $138K | |
| 87497 | <1% | 1,815 | $137K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 613 | $135K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,212 | $130K |
| 99417 | Prolong home eval add 15m | <1% | 1,598 | $123K |
| 80197 | <1% | 2,753 | $119K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,513 | $119K |
| 96415 | <1% | 1,710 | $118K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 458 | $115K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,694 | $115K |
| 78812 | <1% | 25 | $110K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 932 | $109K |
| 72082 | <1% | 1,290 | $106K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,862 | $105K |
| 90686 | <1% | 4,335 | $104K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,791 | $101K |
| 92522 | <1% | 461 | $98K | |
| 76536 | <1% | 1,042 | $97K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 883 | $94K |
| 31575 | <1% | 1,140 | $90K | |
| 84600 | <1% | 2,275 | $86K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 148 | $85K |
| 93975 | <1% | 191 | $83K | |
| 88185 | <1% | 142 | $82K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,407 | $81K |
| 99199 | Unlisted special service, procedure or report | <1% | 1,019 | $80K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,074 | $76K |
| 82670 | <1% | 1,460 | $74K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 714 | $69K |
| 84100 | <1% | 5,149 | $69K | |
| 94010 | <1% | 1,582 | $69K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 102 | $68K |
| 96367 | <1% | 836 | $68K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 662 | $68K |
| 84630 | <1% | 1,205 | $66K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 419 | $63K |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | <1% | 498 | $63K |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 14 | $61K |
| 72156 | <1% | 55 | $59K | |
| G9008 | Coordinated care fee, physician coordinated care oversight services | <1% | 183 | $59K |
| 93320 | <1% | 483 | $56K | |
| 86317 | <1% | 1,525 | $56K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 373 | $54K |
| 86003 | <1% | 357 | $54K | |
| 88112 | <1% | 751 | $54K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,723 | $53K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 583 | $50K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,727 | $50K |
| 82784 | <1% | 2,193 | $47K | |
| 88307 | <1% | 392 | $42K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 5,906 | $42K |
| 82977 | <1% | 2,245 | $42K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,006 | $40K |
| 83520 | <1% | 671 | $40K | |
| 0710 | <1% | 78 | $39K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,299 | $39K |
| 85027 | <1% | 4,266 | $38K | |
| 82803 | <1% | 1,441 | $38K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,679 | $37K |
| 86900 | <1% | 5,902 | $37K | |
| 86901 | <1% | 5,895 | $36K | |
| 86923 | <1% | 425 | $36K | |
| 84439 | <1% | 2,682 | $36K | |
| 84466 | <1% | 1,482 | $36K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 272 | $36K |
| 99368 | <1% | 1,420 | $36K | |
| 91320 | <1% | 121 | $36K | |
| 83615 | <1% | 2,244 | $35K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,646 | $35K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 899 | $35K |
| T1001 | Nursing assessment / evaluation | <1% | 919 | $34K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 321 | $34K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 696 | $34K |
| 82947 | <1% | 4,139 | $33K | |
| 82728 | <1% | 1,562 | $33K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,372 | $33K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 885 | $32K |
| 96417 | <1% | 524 | $32K | |
| 85610 | <1% | 4,090 | $31K | |
| 86850 | <1% | 5,147 | $31K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,161 | $30K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,976 | $30K |
| 92700 | <1% | 193 | $29K | |
| 0761 | <1% | 809 | $29K | |
| Z7500 | <1% | 837 | $28K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 159 | $28K |
| 93321 | <1% | 335 | $27K | |
| 80061 | Lipid panel | <1% | 1,021 | $27K |
| 83993 | <1% | 636 | $27K | |
| 0360 | <1% | 143 | $27K | |
| 92060 | <1% | 1,460 | $27K | |
| 82565 | <1% | 3,653 | $27K | |
| 73630 | <1% | 617 | $27K | |
| 93296 | <1% | 220 | $27K | |
| 87340 | <1% | 1,523 | $26K | |
| 99401 | <1% | 786 | $25K | |
| 90656 | <1% | 811 | $25K | |
| 0270 | <1% | 175 | $24K | |
| 92550 | <1% | 276 | $24K | |
| 92552 | <1% | 232 | $24K | |
| 86140 | <1% | 2,719 | $24K | |
| 73110 | <1% | 573 | $24K | |
| 88304 | <1% | 381 | $23K | |
| 86704 | <1% | 1,227 | $23K | |
| 82570 | <1% | 2,030 | $23K | |
| 0004A | <1% | 575 | $23K | |
| 82040 | <1% | 2,121 | $22K | |
| 77336 | <1% | 258 | $22K | |
| 84460 | <1% | 3,241 | $22K | |
| 86803 | <1% | 1,072 | $22K | |
| 83655 | <1% | 2,405 | $22K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 643 | $22K |
| 84450 | <1% | 3,153 | $22K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,551 | $21K |
| 82525 | <1% | 805 | $21K | |
| 86360 | <1% | 304 | $21K | |
| 81001 | <1% | 2,571 | $20K | |
| 77073 | <1% | 408 | $20K | |
| 83540 | <1% | 1,569 | $20K | |
| 82247 | <1% | 2,618 | $19K | |
| 0064A | <1% | 481 | $19K | |
| 83880 | <1% | 356 | $19K | |
| 84156 | <1% | 1,798 | $19K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,755 | $19K |
| 98967 | <1% | 516 | $18K | |
| 59025 | Fetal non-stress test | <1% | 838 | $18K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,576 | $18K |
| 93356 | <1% | 186 | $18K | |
| 0071A | <1% | 440 | $18K | |
| 83605 | <1% | 1,062 | $17K | |
| 90677 | <1% | 44 | $17K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 68 | $17K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 293 | $16K |
| 77074 | <1% | 231 | $16K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 293 | $16K |
| 87070 | <1% | 987 | $16K | |
| 0072A | <1% | 402 | $16K | |
| 99366 | <1% | 606 | $16K | |
| 86359 | <1% | 283 | $16K | |
| 73562 | <1% | 396 | $16K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,449 | $15K |
| 71045 | Radiologic examination, chest; single view | <1% | 636 | $15K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 250 | $15K |
| 88184 | <1% | 157 | $15K | |
| 83690 | <1% | 1,340 | $15K | |
| 94729 | <1% | 141 | $15K | |
| 84305 | <1% | 272 | $14K | |
| 84075 | <1% | 2,362 | $14K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,614 | $14K |
| 86357 | <1% | 260 | $14K | |
| 77300 | <1% | 43 | $14K | |
| 86481 | <1% | 90 | $14K | |
| 86355 | <1% | 259 | $14K | |
| 85730 | <1% | 1,210 | $14K | |
| 92570 | <1% | 158 | $13K | |
| 0002A | <1% | 325 | $13K | |
| 82610 | <1% | 370 | $13K | |
| 97039 | <1% | 442 | $12K | |
| 92083 | <1% | 676 | $12K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 111 | $12K |
| 73030 | <1% | 240 | $12K | |
| 86665 | <1% | 165 | $12K | |
| 73610 | <1% | 245 | $12K | |
| 85651 | <1% | 2,545 | $12K | |
| 92579 | <1% | 75 | $12K | |
| 0001A | <1% | 383 | $12K | |
| 0054A | <1% | 284 | $11K | |
| 70543 | <1% | 26 | $11K | |
| 0124A | <1% | 286 | $11K | |
| 72170 | <1% | 288 | $11K | |
| 80051 | <1% | 1,103 | $11K | |
| 77080 | <1% | 166 | $11K | |
| 83970 | <1% | 135 | $10K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 13 | $10K |
| 97750 | <1% | 97 | $10K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 114 | $10K |
| 86644 | <1% | 527 | $10K | |
| 88313 | <1% | 222 | $10K | |
| 81003 | <1% | 2,097 | $10K | |
| 82962 | <1% | 1,357 | $10K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 103 | $10K |
| 74018 | <1% | 314 | $10K | |
| 73080 | <1% | 219 | $9K | |
| 87077 | <1% | 497 | $9K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 118 | $9K |
| 72141 | <1% | 12 | $9K | |
| 82248 | <1% | 595 | $9K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,831 | $9K |
| H1003 | Prenatal care, at-risk enhanced service; education | <1% | 345 | $8K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,612 | $8K |
| 90739 | <1% | 19 | $8K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 57 | $8K |
| 82105 | <1% | 63 | $8K | |
| 86592 | <1% | 808 | $8K | |
| 73130 | <1% | 177 | $8K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 16 | $8K |
| S0265 | Genetic counseling, under physician supervision, each 15 minutes | <1% | 80 | $8K |
| 92250 | <1% | 323 | $8K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 42 | $8K |
| 83519 | <1% | 182 | $8K | |
| 31579 | <1% | 96 | $8K | |
| 84295 | <1% | 916 | $8K | |
| 97802 | <1% | 151 | $8K | |
| 95819 | <1% | 112 | $8K | |
| V2632 | Posterior chamber intraocular lens | <1% | 19 | $8K |
| 90480 | <1% | 188 | $8K | |
| 84484 | <1% | 424 | $7K | |
| 0134A | <1% | 190 | $7K | |
| 90750 | <1% | 13 | $7K | |
| 84445 | <1% | 174 | $7K | |
| 84425 | <1% | 377 | $7K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 132 | $7K |
| 84520 | <1% | 1,150 | $7K | |
| 72083 | <1% | 109 | $7K | |
| 86664 | <1% | 213 | $7K | |
| 90651 | <1% | 22 | $7K | |
| A6250 | Skin sealants, protectants, moisturizers, ointments, any type, any size | <1% | 967 | $7K |
| 72100 | <1% | 120 | $7K | |
| 87205 | <1% | 691 | $7K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 71 | $7K |
| 87338 | <1% | 183 | $7K | |
| 87536 | <1% | 42 | $7K | |
| 87088 | <1% | 602 | $7K | |
| 84481 | <1% | 255 | $7K | |
| 83001 | <1% | 184 | $7K | |
| 84132 | <1% | 952 | $6K | |
| Z9725 | <1% | 148 | $6K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 15 | $6K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 400 | $6K |
| 87631 | <1% | 53 | $6K | |
| 69210 | <1% | 315 | $6K | |
| 83921 | <1% | 397 | $6K | |
| 99284 | Emergency room visit (serious) | <1% | 64 | $6K |
| 86160 | <1% | 40 | $6K | |
| 76825 | <1% | 40 | $6K | |
| 82397 | <1% | 101 | $6K | |
| 96910 | <1% | 150 | $5K | |
| 76937 | <1% | 148 | $5K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 53 | $5K |
| 82310 | <1% | 669 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,384 | $5K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 15 | $5K |
| 73560 | <1% | 178 | $5K | |
| 84590 | <1% | 393 | $5K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $5K |
| H1001 | Prenatal care, at-risk enhanced service; antepartum management | <1% | 30 | $5K |
| 0012A | <1% | 149 | $5K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 133 | $5K |
| 73502 | <1% | 72 | $5K | |
| 86777 | <1% | 137 | $4K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 19 | $4K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 101 | $4K |
| 46600 | <1% | 148 | $4K | |
| 76827 | <1% | 40 | $4K | |
| 0011A | <1% | 146 | $4K | |
| 87186 | <1% | 184 | $4K | |
| 85018 | <1% | 1,108 | $4K | |
| 0003A | <1% | 94 | $4K | |
| 93308 | <1% | 14 | $4K | |
| 92526 | <1% | 36 | $4K | |
| 76830 | Ultrasound, transvaginal | <1% | 28 | $4K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,323 | $4K |
| 97803 | <1% | 51 | $4K | |
| 84702 | <1% | 96 | $3K | |
| 93971 | <1% | 18 | $3K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 801 | $3K |
| 90715 | <1% | 30 | $3K | |
| 73590 | <1% | 64 | $3K | |
| 31231 | <1% | 117 | $3K | |
| 0154A | <1% | 73 | $3K | |
| 93270 | <1% | 41 | $3K | |
| 82607 | <1% | 87 | $3K | |
| 95117 | <1% | 111 | $3K | |
| 0081A | <1% | 65 | $3K | |
| 83521 | <1% | 27 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,302 | $3K |
| 0074A | <1% | 63 | $3K | |
| 0160 | <1% | 22 | $2K | |
| 90662 | <1% | 12 | $2K | |
| 84207 | <1% | 75 | $2K | |
| 84255 | <1% | 73 | $2K | |
| 93225 | <1% | 28 | $2K | |
| 90620 | <1% | 16 | $2K | |
| 88173 | <1% | 96 | $2K | |
| 87075 | <1% | 122 | $2K | |
| 72050 | <1% | 28 | $2K | |
| 84153 | <1% | 52 | $2K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 701 | $2K |
| 88323 | <1% | 66 | $2K | |
| 59430 | <1% | 13 | $2K | |
| 83021 | <1% | 95 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 23 | $2K |
| 92555 | <1% | 43 | $2K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 14 | $2K |
| 87081 | <1% | 120 | $2K | |
| 93017 | <1% | 13 | $2K | |
| Z7502 | <1% | 50 | $2K | |
| 84403 | <1% | 34 | $2K | |
| 93304 | <1% | 15 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 24 | $2K |
| 95886 | <1% | 14 | $2K | |
| 87517 | <1% | 18 | $2K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 18 | $2K |
| 86780 | <1% | 110 | $2K | |
| 86334 | <1% | 26 | $2K | |
| 0082A | <1% | 39 | $2K | |
| 83789 | <1% | 24 | $1K | |
| 71020 | <1% | 61 | $1K | |
| 83020 | <1% | 95 | $1K | |
| 84446 | <1% | 159 | $1K | |
| 86833 | <1% | 17 | $1K | |
| 86832 | <1% | 17 | $1K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 12 | $1K |
| 94060 | <1% | 12 | $1K | |
| 76000 | <1% | 40 | $1K | |
| 88142 | <1% | 199 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 145 | $1K |
| 73552 | <1% | 27 | $1K | |
| 82172 | <1% | 40 | $1K | |
| 96409 | <1% | 29 | $1K | |
| 73140 | <1% | 43 | $1K | |
| 76820 | <1% | 14 | $1K | |
| 82378 | <1% | 28 | $1K | |
| 74455 | <1% | 12 | $1K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 123 | $1K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 664 | $1K |
| 0031A | <1% | 27 | $1K | |
| 82043 | <1% | 90 | $1K | |
| 84165 | <1% | 44 | $1K | |
| 82627 | <1% | 53 | $1K | |
| 87102 | <1% | 49 | $1K | |
| 0083A | <1% | 24 | $960.00 | |
| 84402 | <1% | 20 | $956.24 | |
| 84550 | <1% | 106 | $949.41 | |
| 82274 | <1% | 29 | $920.41 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 16 | $903.22 |
| 88172 | <1% | 71 | $903.01 | |
| 88312 | <1% | 13 | $882.17 | |
| 82550 | <1% | 65 | $872.66 | |
| 87206 | <1% | 45 | $872.44 | |
| 92556 | <1% | 25 | $862.97 | |
| 82746 | <1% | 29 | $825.10 | |
| 86038 | <1% | 37 | $821.17 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 434 | $815.31 |
| 82435 | <1% | 115 | $777.47 | |
| 0111A | <1% | 19 | $760.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 44 | $746.78 |
| 86364 | <1% | 24 | $736.33 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 12 | $707.52 |
| 82533 | <1% | 15 | $695.40 | |
| 92626 | <1% | 12 | $683.96 | |
| 0052A | <1% | 17 | $680.00 | |
| 82374 | <1% | 109 | $636.25 | |
| 85045 | <1% | 90 | $635.95 | |
| 81025 | <1% | 75 | $619.50 | |
| 10005 | <1% | 15 | $608.33 | |
| 64615 | <1% | 12 | $606.83 | |
| 0112A | <1% | 15 | $600.00 | |
| 90648 | <1% | 24 | $599.60 | |
| 87040 | <1% | 29 | $594.92 | |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | <1% | 58 | $577.00 |
| 99354 | <1% | 17 | $576.00 | |
| 77072 | <1% | 25 | $538.09 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 47 | $529.89 |
| 94760 | <1% | 26 | $498.70 | |
| 0051A | <1% | 12 | $480.00 | |
| 86790 | <1% | 44 | $478.76 | |
| 91319 | <1% | 25 | $453.60 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 139 | $438.36 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 36 | $394.04 |
| 17110 | <1% | 24 | $393.18 | |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | <1% | 13 | $371.87 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 18 | $368.50 |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | <1% | 13 | $361.40 |
| 84432 | <1% | 12 | $341.34 | |
| 90723 | <1% | 13 | $327.60 | |
| 46607 | <1% | 13 | $309.50 | |
| 83695 | <1% | 14 | $304.48 | |
| 90633 | <1% | 12 | $302.40 | |
| 87147 | <1% | 20 | $284.46 | |
| 86800 | <1% | 13 | $275.09 | |
| 85379 | <1% | 14 | $272.37 | |
| 82365 | <1% | 13 | $234.00 | |
| 95115 | <1% | 17 | $226.96 | |
| 94664 | <1% | 14 | $224.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 14 | $220.35 |
| 86774 | <1% | 13 | $218.58 | |
| 89051 | <1% | 82 | $216.64 | |
| 86762 | <1% | 13 | $201.95 | |
| 86200 | <1% | 12 | $173.80 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 12 | $165.21 |
| 86225 | <1% | 12 | $146.49 | |
| 84270 | <1% | 12 | $145.40 | |
| 11900 | <1% | 12 | $145.23 | |
| 88300 | <1% | 38 | $141.18 | |
| 81002 | <1% | 30 | $140.19 | |
| 86431 | <1% | 13 | $136.81 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 96 | $101.79 |
| 82985 | <1% | 12 | $97.44 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 41 | $25.03 |
| 85008 | <1% | 15 | $17.22 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 12 | $13.69 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 13 | $11.30 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 202 | $2.38 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGUNASEKARAN, SURESH (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| University of California, San Francisco | San Francisco, CA | $20.99M |
| University of California San Francisco | San Francisco, CA | $1.78M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.